Evidence map›Paper›PMID 26779626›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Cyfip1 is downregulated in acute lymphoblastic leukemia and may be a potential biomarker in acute lymphoblastic leukemia.

Xu Chen, Lingyan Qin, Ping Li, Wuning Mo

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Prognostic modelling of colorectal cancer based on oxidative stress-related genes.Journal of cancer research and clinical oncology · 2023
    Article
  5. Article
  6. Application effect analysis of peak inspiratory pressure (PArchives of medical science : AMS · 2023
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xu ChenDepartment of Clinical Laboratory, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, People's Republic of China.
Lingyan QinDepartment of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, People's Republic of China.
Ping LiDepartment of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, People's Republic of China.
Wuning MoDepartment of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, People's Republic of China. mown16300@126.com.
First Affiliated Hospital of GuangXi Medical University · CNGuangxi Medical University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to analyze the expression of Cyfip1 in acute lymphoblastic leukemia (ALL) and its correlations with clinical pathologic features. A total of 86 ALL samples and 32 normal peripheral blood lymphocyte (PBL) samples were enrolled in our study. mRNA expression of the Cyfip1 was assessed by real-time fluorescent relatively quantitative PCR, and Cyfip1 protein expression was evaluated by Western blot analysis. As a result, both mRNA and protein expression levels of Cyfip1 were significantly lower in ALL patients than those in the control samples (P = 0.025 and 0.000, respectively). Moreover, both mRNA and protein expression of both had an inverse relation with lymph node metastasis (P = 0.015 and 0.007, respectively), In conclusion, detecting mRNA and protein expression of Cyfip1 could provide clinically significant information relevant to diagnosis, progression, and treatment modalities for ALL, and Cyfip1 may serve as a potential biomarker for diagnosis and prognosis in ALL.

Indexed as

Adaptor Proteins, Signal TransducingAdolescentBiomarkers, TumorChildDown-RegulationFemaleHumansLymphatic MetastasisMalePrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRNA, MessengerAdaptor Proteins, Signal TransducingBiomarkers, TumorCYFIP1 protein, humanRNA, MessengerAcute lymphoblastic leukemiaCyfip1DiagnosisPrognosis

Identifiers

PMID26779626
OpenAlexW2236854599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.